CVRX
CVRx, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.35
+3.85%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.30
From 52W high−87.51%
Volume357819.00
Market cap$35.97M
P/E (TTM)—
P/S (TTM)0.6x
Div yield—
Key dataOct 19, 2026
Open
$1.30
From 52W high
−87.51%
Volume
357819.00
Market cap
$35.97M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
23.2
MomentumView details →
1D Return
+3.85%
YTD Return
−81.69%
SummaryUpdated Jun 1, 2026
CVRx, Inc. (NASDAQ:CVRX) is a commercial-stage medical device company founded in 2000 and headquartered in Minneapolis, Minnesota. The company went public in June 2021 and specializes in developing neuromodulation solutions for cardiovascular diseases. CVRx has established itself as a pioneer in the emerging field of cardiovascular neuromodulation, focusing primarily on treating heart failure through its flagship Barostim device. After more than two decades of development and clinical testing, the company has successfully commercialized its technology and is actively expanding its market presence in the United States and Europe.
Similar companies
Latest newsMore news →
CVRx announced the schedule of scientific presentations featuring its Barostim neuromodulation therapy at the Heart Failure Society of America Annual Scientific Meeting 2026.20d agoCVRx, Inc. appointed John Landry as Chief Financial Officer effective October 12, 2026, succeeding Jared Oasheim, who resigned.28d ago